Ixekizumab in the Treatment of Bullous Pemphigoid
Part of paid clinical trials in Scottsdale, Arizona.
- Sponsor
- Mayo Clinic
- Study ID
- NCT03099538
- Phase
- PHASE2
- Status
- Completed
Conditions
- Bullous Pemphigoid
- Pemphigoid
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Ixekizumab — DRUGSubcutaneous injection
Study Details
Recently, Interleukin (IL)-17 has been identified as a key driver of chronic inflammation in Bullous Pemphigoid (BP). Ixekizumab is a recombinant high-affinity fully human monoclonal antibody that targets IL-17A Immunoglobulin gamma-1 (IgG1)/kappa-class. The purpose of this study is to determine the effect of Ixekizumab on BP patients.
Key Dates
- Start date
- Aug 15, 2017
- Status verified
- May 2020
- Primary completion
- Jun 6, 2019
- Completion
- Jun 6, 2019
Study Design
- Enrollment
- 4 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: IxekizumabIxekizumab subcutaneous 160mg week 0, 80mg weeks 2, 4, 6, 8, 10, 12.
Primary Outcome Measure
Cessation of Blister Formation [ Time Frame: Up to 12 weeks ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Mayo Clinic | Scottsdale | Arizona | 85259 | - |
Find similar trials in Scottsdale, AZ
By research site
Related Studies
- Autoimmune Blistering Diseases StudyRecruiting · University of Pennsylvania · Philadelphia, Pennsylvania